Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: Lessons from a retrospective multicentric cohort of 383 patients.
Fiche publication
Date publication
janvier 2022
Journal
Surgery
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LAKKIS Zaher
Tous les auteurs :
Collard MK, Rullier E, Panis Y, Karoui M, Benoist S, Tuech JJ, Alves A, Laforest A, Mege D, Cazelles A, Beyer-Berjot L, Christou N, Cotte E, Lakkis Z, O'Connell L, Parc Y, Piessen G, Lefevre JH,
Lien Pubmed
Résumé
A better understanding of pathological features and oncological survival in ypT0 rectal cancer after neoadjuvant chemoradiotherapy is required to improve patient selection criteria for rectal-preserving approach by local excision. Our aim was to define risk of lymph node metastasis and oncological outcomes in ypT0 rectal cancer after chemoradiotherapy and total mesorectal excision.
Référence
Surgery. 2022 Jan 22;: